Teladoc Health Statistics
Total Valuation
Teladoc Health has a market cap or net worth of $1.77 billion. The enterprise value is $1.95 billion.
| Market Cap | 1.77B |
| Enterprise Value | 1.95B |
Important Dates
The last earnings date was Wednesday, October 28, 2026, after market close.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Teladoc Health has 182.29 million shares outstanding. The number of shares has increased by 2.87% in one year.
| Current Share Class | 182.29M |
| Shares Outstanding | 182.29M |
| Shares Change (YoY) | +2.87% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 86.45% |
| Float | 181.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.72 |
| Forward PS | 0.75 |
| PB Ratio | 1.25 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 6.75 |
| P/OCF Ratio | 6.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.83, with an EV/FCF ratio of 7.45.
| EV / Earnings | n/a |
| EV / Sales | 0.79 |
| EV / EBITDA | 22.83 |
| EV / EBIT | n/a |
| EV / FCF | 7.45 |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 0.80.
| Current Ratio | 0.87 |
| Quick Ratio | 0.77 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | 10.45 |
| Debt / FCF | 3.95 |
| Interest Coverage | -6.50 |
Financial Efficiency
Return on equity (ROE) is -11.52% and return on invested capital (ROIC) is -3.47%.
| Return on Equity (ROE) | -11.52% |
| Return on Assets (ROA) | -2.93% |
| Return on Invested Capital (ROIC) | -3.47% |
| Return on Capital Employed (ROCE) | -9.73% |
| Weighted Average Cost of Capital (WACC) | 10.69% |
| Revenue Per Employee | $440,740 |
| Profits Per Employee | -$27,647 |
| Employee Count | 5,600 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 21.96 |
Taxes
| Income Tax | -3.83M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.10% in the last 52 weeks. The beta is 2.14, so Teladoc Health's price volatility has been higher than the market average.
| Beta (5Y) | 2.14 |
| 52-Week Price Change | +19.10% |
| 50-Day Moving Average | 6.40 |
| 200-Day Moving Average | 6.51 |
| Relative Strength Index (RSI) | 83.67 |
| Average Volume (20 Days) | 5,037,690 |
Short Selling Information
The latest short interest is 32.07 million, so 17.59% of the outstanding shares have been sold short.
| Short Interest | 32.07M |
| Short Previous Month | 27.63M |
| Short % of Shares Out | 17.59% |
| Short % of Float | 17.71% |
| Short Ratio (days to cover) | 8.82 |
Income Statement
In the last 12 months, Teladoc Health had revenue of $2.47 billion and -$154.82 million in losses. Loss per share was -$0.86.
| Revenue | 2.47B |
| Gross Profit | 1.69B |
| Operating Income | -132.33M |
| Pretax Income | -158.65M |
| Net Income | -154.82M |
| EBITDA | 85.54M |
| EBIT | -132.33M |
| Loss Per Share | -$0.86 |
Balance Sheet
The company has $849.91 million in cash and $1.04 billion in debt, with a net cash position of -$185.24 million or -$1.02 per share.
| Cash & Cash Equivalents | 849.91M |
| Total Debt | 1.04B |
| Net Cash | -185.24M |
| Net Cash Per Share | -$1.02 |
| Equity (Book Value) | 1.29B |
| Book Value Per Share | 7.10 |
| Working Capital | -189.49M |
Cash Flow
In the last 12 months, operating cash flow was $268.38 million and capital expenditures -$6.42 million, giving a free cash flow of $261.96 million.
| Operating Cash Flow | 268.38M |
| Capital Expenditures | -6.42M |
| Depreciation & Amortization | 217.87M |
| Net Borrowing | n/a |
| Free Cash Flow | 261.96M |
| FCF Per Share | $1.44 |
Margins
Gross margin is 68.57%, with operating and profit margins of -5.36% and -6.27%.
| Gross Margin | 68.57% |
| Operating Margin | -5.36% |
| Pretax Margin | -6.43% |
| Profit Margin | -6.27% |
| EBITDA Margin | 3.47% |
| EBIT Margin | -5.36% |
| FCF Margin | 10.61% |
Dividends & Yields
Teladoc Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.87% |
| Shareholder Yield | -2.87% |
| Earnings Yield | -8.87% |
| FCF Yield | 14.82% |
Analyst Forecast
The average price target for Teladoc Health is $8.58, which is -11.47% lower than the current price. The consensus rating is "Hold".
| Price Target | $8.58 |
| Price Target Difference | -11.47% |
| Analyst Consensus | Hold |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | -2.13% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Teladoc Health has an Altman Z-Score of -7.21 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.21 |
| Piotroski F-Score | 3 |